SRZNSurrozen, Inc.
$28.01+104% 1Y
$28.01
$11.8052 weeks$34.13
SRZN in its own filings
SRZN's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
131
Events found in the filings · across 492 filings · the record starts in 2020
- Hard flags
- 4
Hard flags
- Most recent filing
- Oct 2, 2026
Most recent filing · Form 8-K
- Record starts
- Oct 23, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 6, 2026
- Restatement admitted (non-reliance)historical
- 2021-05-14
- Change in certifying accountanthistorical
- 2021-08-17
- Late periodic report2 occurrences
- 2024-04-02
- Delisting notice / listing-rule failure2 occurrences
- 2023-07-05
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2026-08-07
- SEC comment-letter activity27 occurrences
- 2025-05-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 2, 2026On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development.Other event · Form 8-K
- Aug 6, 2026Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 6, 2026Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Mar 23, 2026Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Jan 30, 2026Resignation of Director On January 26, 2026, Shao-Lee Lin, M.D., Ph.D. resigned from the Board of Directors of Surrozen, Inc., or the Company, effective immediately.Director or officer change · Form 8-K
- Nov 7, 2025Appointment of Chief Financial Officer On November 6, 2025, the board of directors of the Company appointed Andrew Maleki, age 36, to the position of Chief Financial Officer, effective November 12, 2025, to serve as the Company’s principal financial and accounting officer.Earnings release · Form 8-K
- Oct 17, 2025On October 14, 2025, Surrozen, Inc. (the “Company”) received notice from TCGFB, Inc. (“TCGFB”) that TCGFB has elected to terminate the Collaboration Agreement (the “Collaboration Agreement”) between TCGFB and the Company, dated October 31, 2024.Material agreement terminated · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…